While Merck's oncology powerhouse Keytruda delivered another multibillion-dollar sales haul in the third quarter, regional ...
Its top-selling cancer drug, Keytruda, is a standout product with global recognition ... from rapid international launches.
The company saw strong sales from its top-selling cancer drug Keytruda, recently launched treatments and its animal health ...
Zacks.com on MSN23d
Merck Stock Down More Than 14% in 6 Months: Buy, Sell or Hold?Merck’s Animal health and vaccine products are core growth drivers. It has a strong cancer pipeline, including Keytruda.
On Thursday, Merck & Co Inc (NYSE:MRK) reported third-quarter sales of $16.66 billion, up 4% year over year, beating the ...
The company’s pneumococcal shot, called Prevnar, is one of its best-selling products with about $6 billion in annual sales. Merck’s recently approved vaccine, however, gives Pfizer some major ...
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced results from STRIDE-8, a Phase 3 trial evaluating CAPVAXIVEâ„¢ (Pneumococcal ...
Merck's consistent dividend payments over 34 years, healthy balance sheet, and attractive valuation highlight its investment ...
Merck reported a decline of 11% in sales of Gardasil to $2.31 billion, a vaccine that prevents cancer ... promising momentum from both commercial products like Winrevair and Capvaxive and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback